Predictors of Somatostatin Analog (SSA) Dose Escalations (DEs) Above Recommended Dosing Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treated at a Tertiary Referral Center

Jessica J. Jalbert, PhD, 1 Roman Cassigneul, MSc, 1,2 Jie Meng MSc, 1 Anemarie Lam Ba, 1 Lauren K. Brash, MPh, 1 Sonia J. Pulger, MPH, 1 Anthony Berthon, PharmD, 2 Sylvie Gabriel, MD, 1,3 Jerome Dinet, PharmD, 1 Matthew H. Kulke, MD, 1

(1) Analytical CASAR International, New York, NY; (2) Analytical CASAR International, Lorient, Germany; (3) Dana-Farber Cancer Institute, Boston, MA; (4) Ipsen Biopharmaceuticals Inc., Reading, Algy, NJ; (5) Ipsen Pharma SAS, Boulogne-Billancourt Cedex, France

Background

- Long-acting SSAs are commonly used to treat symptoms and progression of metastatic gastr These patients are eligible for DFCI’s Outpatient pharmacy retrospective cohort study, which is open through December 31, 2019, and will be presented at the 10th Annual Symposium of the Neuroendocrine Tumor Research Program in Philadelphia, PA, USA, October 18-19, 2017.

This study includes all the potential variables related to dose escalations. However, we acknowledge that some baseline variables of dose escalations and the dispensing of the comparator group share the same value, as they come from the same patient, and these variables might be correlated.

Conclusions

- SSA DEs above recommended dosing was common among patients studied, especially among those with midgut NETs and greater disease burden.
- The prior localized, treatment, recent systemic treatment, and the prior SSA DEs are all associated with DEs.

Limitations

- The prior localized, treatment, recent systemic treatment, and the prior SSA DEs are all associated with DEs.

Disclosures

- A.J.A. was an employee of Analytical CASAR Int. at the time of analysis. R.C., and J.M. have been employees of Ipsen Biopharmaceuticals Inc., which conducts research funding from Ipsen. M.M., L.A.B., and A.L. received research funding from Ipsen. S.J.P. is the employee of Ipsen Biopharmaceuticals Inc. S.G., J.D., and A.B. are employees of Ipsen Pharma SAS.

This study was sponsored by Ipsen.